NEW @ohsunews.bsky.social study: a combination of ART, broadly neutralizing antibodies + CCR5-blocking #leronlimab, started within ~3 days of #HIV #infection prevented viral rebound in newborn nonhuman primates. Intervene early. Promising. Looking forward to human #clinicaltrials. lnkd.in/p/eB3YA8YV